197 related articles for article (PubMed ID: 22477184)
1. Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases.
Lim KM; Park YH
Arch Pharm Res; 2012 Mar; 35(3):393-6. PubMed ID: 22477184
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of PAC-14028 cream - a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial.
Lee YW; Won CH; Jung K; Nam HJ; Choi G; Park YH; Park M; Kim B
Br J Dermatol; 2019 May; 180(5):1030-1038. PubMed ID: 30623408
[TBL] [Abstract][Full Text] [Related]
3. Upcoming topical TRPV1 anti-pruritic compounds.
Lee KP; Koshelev MV
Dermatol Online J; 2020 Sep; 26(9):. PubMed ID: 33054935
[TBL] [Abstract][Full Text] [Related]
4. Antipruritic effects of TRPV1 antagonist in murine atopic dermatitis and itching models.
Yun JW; Seo JA; Jang WH; Koh HJ; Bae IH; Park YH; Lim KM
J Invest Dermatol; 2011 Jul; 131(7):1576-9. PubMed ID: 21471988
[No Abstract] [Full Text] [Related]
5. TRPV1 antagonist can suppress the atopic dermatitis-like symptoms by accelerating skin barrier recovery.
Yun JW; Seo JA; Jeong YS; Bae IH; Jang WH; Lee J; Kim SY; Shin SS; Woo BY; Lee KW; Lim KM; Park YH
J Dermatol Sci; 2011 Apr; 62(1):8-15. PubMed ID: 21345654
[TBL] [Abstract][Full Text] [Related]
6. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.
Honore P; Chandran P; Hernandez G; Gauvin DM; Mikusa JP; Zhong C; Joshi SK; Ghilardi JR; Sevcik MA; Fryer RM; Segreti JA; Banfor PN; Marsh K; Neelands T; Bayburt E; Daanen JF; Gomtsyan A; Lee CH; Kort ME; Reilly RM; Surowy CS; Kym PR; Mantyh PW; Sullivan JP; Jarvis MF; Faltynek CR
Pain; 2009 Mar; 142(1-2):27-35. PubMed ID: 19135797
[TBL] [Abstract][Full Text] [Related]
7. Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis in mice.
Arai I; Takaoka A; Hashimoto Y; Honma Y; Koizumi C; Futaki N; Sugimoto M; Takahashi N; Inoue T; Nakanishi Y; Sakurai T; Tanami T; Yagi M; Ono N; Nakaike S
Eur J Pharmacol; 2007 Feb; 556(1-3):207-14. PubMed ID: 17141215
[TBL] [Abstract][Full Text] [Related]
8. Topical capsaicin. The fire of a 'hot' medicine is reignited.
Papoiu AD; Yosipovitch G
Expert Opin Pharmacother; 2010 Jun; 11(8):1359-71. PubMed ID: 20446852
[TBL] [Abstract][Full Text] [Related]
9. (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo.
Surowy CS; Neelands TR; Bianchi BR; McGaraughty S; El Kouhen R; Han P; Chu KL; McDonald HA; Vos M; Niforatos W; Bayburt EK; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
J Pharmacol Exp Ther; 2008 Sep; 326(3):879-88. PubMed ID: 18515644
[TBL] [Abstract][Full Text] [Related]
10. Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect.
Watabiki T; Kiso T; Kuramochi T; Yonezawa K; Tsuji N; Kohara A; Kakimoto S; Aoki T; Matsuoka N
J Pharmacol Exp Ther; 2011 Mar; 336(3):743-50. PubMed ID: 21098091
[TBL] [Abstract][Full Text] [Related]
11. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.
Lehto SG; Tamir R; Deng H; Klionsky L; Kuang R; Le A; Lee D; Louis JC; Magal E; Manning BH; Rubino J; Surapaneni S; Tamayo N; Wang T; Wang J; Wang J; Wang W; Youngblood B; Zhang M; Zhu D; Norman MH; Gavva NR
J Pharmacol Exp Ther; 2008 Jul; 326(1):218-29. PubMed ID: 18420600
[TBL] [Abstract][Full Text] [Related]
12. A TRPV1 antagonist, PAC-14028 does not increase the risk of tumorigenesis in chemically induced mouse skin carcinogenesis.
Choi JK; Cho W; Lee JH; Choi G; Park M
Regul Toxicol Pharmacol; 2020 Apr; 112():104613. PubMed ID: 32044384
[TBL] [Abstract][Full Text] [Related]
13. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade.
Gavva NR; Bannon AW; Hovland DN; Lehto SG; Klionsky L; Surapaneni S; Immke DC; Henley C; Arik L; Bak A; Davis J; Ernst N; Hever G; Kuang R; Shi L; Tamir R; Wang J; Wang W; Zajic G; Zhu D; Norman MH; Louis JC; Magal E; Treanor JJ
J Pharmacol Exp Ther; 2007 Oct; 323(1):128-37. PubMed ID: 17652633
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists.
Blum CA; Caldwell T; Zheng X; Bakthavatchalam R; Capitosti S; Brielmann H; De Lombaert S; Kershaw MT; Matson D; Krause JE; Cortright D; Crandall M; Martin WJ; Murphy BA; Boyce S; Jones AB; Mason G; Rycroft W; Perrett H; Conley R; Burnaby-Davies N; Chenard BL; Hodgetts KJ
J Med Chem; 2010 Apr; 53(8):3330-48. PubMed ID: 20307063
[TBL] [Abstract][Full Text] [Related]
15. Itch Management: Treatments under Development.
Pereira MP; Ständer S
Curr Probl Dermatol; 2016; 50():71-6. PubMed ID: 27578074
[TBL] [Abstract][Full Text] [Related]
16. Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo.
Christoph T; Grünweller A; Mika J; Schäfer MK; Wade EJ; Weihe E; Erdmann VA; Frank R; Gillen C; Kurreck J
Biochem Biophys Res Commun; 2006 Nov; 350(1):238-43. PubMed ID: 16996476
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the Warm Temperature-Activated Ca
Qu Y; Wang G; Sun X; Wang K
Mol Pharmacol; 2019 Sep; 96(3):393-400. PubMed ID: 31308264
[TBL] [Abstract][Full Text] [Related]
18. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept.
Szallasi A; Cortright DN; Blum CA; Eid SR
Nat Rev Drug Discov; 2007 May; 6(5):357-72. PubMed ID: 17464295
[TBL] [Abstract][Full Text] [Related]
19. The anti-pruritic efficacy of TS-022, a prostanoid DP1 receptor agonist, is dependent on the endogenous prostaglandin D2 level in the skin of NC/Nga mice.
Sugimoto M; Arai I; Futaki N; Hashimoto Y; Sakurai T; Honma Y; Nakaike S
Eur J Pharmacol; 2007 Jun; 564(1-3):196-203. PubMed ID: 17328887
[TBL] [Abstract][Full Text] [Related]
20. Role of transient receptor potential ankyrin subfamily member 1 in pruritus induced by endothelin-1.
Liang J; Ji Q; Ji W
Neurosci Lett; 2011 Apr; 492(3):175-8. PubMed ID: 21315802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
